Core Opinion - Eli Lilly (LLY) and Incyte (INCY) received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommending the approval of expanded use of Olumiant (baricitinib) for adolescents aged 12 to less than 18 with severe alopecia areata (AA) [1] Group 1: Clinical Data and Approval Process - The positive CHMP opinion was based on data from the phase III BRAVE-AA-PEDS study, which showed that 42% of patients with severe AA achieved 80% or more scalp hair coverage at 36 weeks after treatment with Olumiant [4][7] - The study specifically investigated children and adolescents with severe AA, supporting the potential expansion of Olumiant as a new treatment option for this demographic [5] - A final decision from the European Commission is expected in the next one to two months, while a decision for the U.S. market is anticipated in the second half of 2026 [1][8] Group 2: Financial Performance and Market Impact - Olumiant generated sales of $1.01 billion in 2025, and successful label expansion for additional indications is expected to drive sales growth in 2026 and beyond [7][8] - Year to date, shares of Eli Lilly have decreased by 2.1%, contrasting with the industry's increase of 5.2% [2]

Core Viewpoint - Eli Lilly's Olumiant (baricitinib) has received a positive opinion from the European Medicines Agency's CHMP for expanded use in adolescents aged 12 to under 18 with severe alopecia areata, based on promising data from the Phase 3 BRAVE-AA-PEDS study [1][2]. Group 1: Clinical Study Results - The Phase 3 BRAVE-AA-PEDS study showed that 42.4% of adolescents treated with Olumiant achieved 80% or more scalp hair coverage at 36 weeks, compared to 4.5% in the placebo group [1]. - Near-complete scalp hair coverage (90%) was achieved by 36.5% of patients on Olumiant, while only 2.3% of those on placebo reached this level [1]. - Significant eyebrow regrowth was observed in 50% of patients on Olumiant, compared to 0% in the placebo group [1]. - Eyelash regrowth was reported in 42.9% of patients treated with Olumiant, versus 14.0% in the placebo group [1]. Group 2: Regulatory and Market Implications - The positive CHMP opinion is a step towards European regulatory approval, with a decision from the European Commission expected in the next one to two months [1]. - Lilly has also submitted Olumiant for approval in the U.S. for treating severe alopecia areata in adolescents, with a decision anticipated in the second half of 2026 [1][2]. - Olumiant is already approved for adult patients with severe alopecia areata in the U.S. and Europe, marking it as the first JAK inhibitor approved for this indication [1][2]. Group 3: Safety and Efficacy Profile - The safety profile of Olumiant in adolescents aligns with previous clinical trials for other conditions, such as juvenile idiopathic arthritis and atopic dermatitis [1]. - Over 14,600 patients have participated in clinical trials involving Olumiant, with more than 1,200 being children and adolescents [1]. - The ongoing BRAVE-AA-PEDS trial includes a cohort of children aged 6 to under 12 years, further expanding the understanding of Olumiant's safety and efficacy in younger populations [1].

Core Insights - AbbVie announced positive topline results from two Phase 3 studies evaluating the safety and efficacy of upadacitinib (RINVOQ) for treating non-segmental vitiligo (NSV) [1][2] Efficacy Results - Upadacitinib achieved co-primary endpoints of a 50% reduction in Total Vitiligo Area Scoring Index (T-VASI 50) and a 75% reduction in Facial Vitiligo Area Scoring Index (F-VASI 75) at week 48 compared to placebo [4][2] - In Study 1, 19.4% of patients on upadacitinib achieved T-VASI 50, while 5.9% in the placebo group did. For F-VASI 75, 25.2% achieved this endpoint compared to 5.9% in the placebo group [3] - In Study 2, 21.5% achieved T-VASI 50 and 23.4% achieved F-VASI 75 on upadacitinib, compared to 5.9% and 6.9% in the placebo group, respectively [3] Safety Profile - The safety profile of upadacitinib was consistent with previous studies, with no new safety signals identified [2] - The most common treatment-emergent adverse events (TEAEs) included upper respiratory tract infections, acne, and nasopharyngitis [3] - Serious adverse events (TESAEs) occurred in 3.9% and 4% of patients in the upadacitinib and placebo groups in Study 1, and 2% and 1% in Study 2, respectively [3] Background on Vitiligo - Vitiligo is a chronic autoimmune disease affecting approximately 0.5% to 2.3% of the global population, with non-segmental vitiligo (NSV) being the most common form [6] - NSV accounts for roughly 84% of vitiligo cases and can lead to significant psychosocial challenges, including depression and anxiety [6] Clinical Trial Design - The trials involved 614 participants across 90 sites worldwide, randomized in a 2:1 ratio to receive either upadacitinib 15 mg or placebo for 48 weeks [6] - Participants who completed the initial period were eligible for a 112-week open-label extension where all received upadacitinib [6]

Core Insights - The BRAVE-AA-PEDS trial is the first and largest study focused on children and adolescents with severe alopecia areata, showing that 71% of adolescents treated with baricitinib 4 mg achieved successful scalp hair regrowth at one year [1][2][4] - Eli Lilly plans to submit the trial data to global regulators for a potential label update for baricitinib, commercially known as Olumiant [1][9][10] Group 1: Trial Results - At one year, 54.1% of patients receiving baricitinib 4 mg and 31% receiving baricitinib 2 mg achieved successful hair regrowth, defined as 80% or more scalp hair coverage [7] - Among patients with severe disease, 71% receiving baricitinib 4 mg and 58.6% receiving baricitinib 2 mg achieved successful hair regrowth [7] - In a post-hoc analysis, 80% of adolescents diagnosed with severe AA less than two years before treatment achieved successful hair regrowth with baricitinib 4 mg [4] Group 2: Safety Profile - The safety profile of baricitinib in adolescents was consistent with that seen in adult trials, with no new safety signals observed after one year [5][8] - Common treatment-emergent adverse events included acne, upper respiratory tract infection, and influenza, with no deaths or major adverse cardiovascular events reported [5][8] Group 3: Future Plans and Context - Lilly intends to enroll a new cohort of children ages 6 to under 12 in the BRAVE-AA-PEDS trial in the next year [9][12] - Baricitinib is the most-researched JAK inhibitor in alopecia areata, with over 1,300 adults and 423 adolescents enrolled in clinical trials [10]

Core Insights - Eli Lilly and Incyte presented late-breaking results showing that 42.4% of adolescents treated with baricitinib 4 mg achieved 80% or more scalp hair coverage at Week 36, indicating significant hair regrowth potential for severe alopecia areata [1][2][3] - The Phase 3 BRAVE-AA-PEDS study demonstrated that baricitinib can provide clinically meaningful improvements in hair regrowth for adolescents, with results comparable to those seen in adults after a longer treatment duration [2][3] - Baricitinib is positioned as a leading treatment option for severe alopecia areata, with ongoing studies expected to provide further data and regulatory discussions in the near future [2][5] Study Results - In the BRAVE-AA-PEDS study, 257 patients were randomized to receive either baricitinib 4 mg, 2 mg, or placebo, with the primary endpoint being a SALT score of ≤20 at Week 36 [1][7] - At Week 36, 60.0% of patients on baricitinib 4 mg and 36.9% on 2 mg saw at least a 50% improvement in their disease, compared to only 5.7% on placebo [3] - Significant eyebrow and eyelash regrowth was also observed, with 50.0% and 42.9% of patients on baricitinib 4 mg achieving notable improvements, respectively [3] Safety Profile - The most common treatment-emergent adverse events included acne, influenza, and upper respiratory tract infections, with a higher frequency of serious adverse events in the placebo group [4] - The safety profile of baricitinib in adolescents aligns with previous findings in trials for juvenile idiopathic arthritis and atopic dermatitis, indicating a consistent safety record [4][5] Regulatory and Market Position - Baricitinib, marketed as Olumiant, is already approved for adult patients with severe alopecia areata and has received regulatory approval for other conditions, including rheumatoid arthritis and atopic dermatitis [5][6] - The company plans to present additional data from the BRAVE-AA-PEDS study at scientific meetings and submit results for peer-reviewed publication, reinforcing its commitment to advancing treatment options for alopecia areata [5][6]